- Home
- LOMA vs AMPH Comparison
LOMA vs AMPH Comparison
Compare LOMA & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOMA | AMPH |
|---|---|---|
| Founded | 1926 | 1996 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LOMA | AMPH |
|---|---|---|
| Price | $11.36 | $28.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $15.00 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 341.3K | 297.9K |
| Earning Date | 03-05-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.06 | ★ 2.27 |
| Revenue | $464,306,268.00 | ★ $723,305,000.00 |
| Revenue This Year | $22.92 | $1.37 |
| Revenue Next Year | $25.84 | $4.84 |
| P/E Ratio | $190.46 | ★ $12.56 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.04 | $20.39 |
| 52 Week High | $14.17 | $32.69 |
Technical Indicators
Market Signals| Indicator | LOMA | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.87 | 57.21 |
| Support Level | $10.39 | $27.24 |
| Resistance Level | $12.05 | $29.09 |
| Average True Range (ATR) | 0.63 | 0.89 |
| MACD | 0.02 | 0.08 |
| Stochastic Oscillator | 51.43 | 73.77 |
Price Performance
Historical ComparisonAbout LOMA Loma Negra Compania Industrial Argentina Sociedad Anonima ADS
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.